BR112013015796A2 - composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica. - Google Patents

composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.

Info

Publication number
BR112013015796A2
BR112013015796A2 BR112013015796A BR112013015796A BR112013015796A2 BR 112013015796 A2 BR112013015796 A2 BR 112013015796A2 BR 112013015796 A BR112013015796 A BR 112013015796A BR 112013015796 A BR112013015796 A BR 112013015796A BR 112013015796 A2 BR112013015796 A2 BR 112013015796A2
Authority
BR
Brazil
Prior art keywords
preparing
imaging agent
agent composition
composition
chelator
Prior art date
Application number
BR112013015796A
Other languages
English (en)
Inventor
Wilson Anthony
Indrevoll Bard
Hiscock Duncan
Eberhard Glaser Matthias
Iveson Peter
Bhalla Rajiv
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/975,425 external-priority patent/US20120165650A1/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BR112013015796A2 publication Critical patent/BR112013015796A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
BR112013015796A 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica. BR112013015796A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/975,425 US20120165650A1 (en) 2010-12-22 2010-12-22 Her2 binders
US201161438297P 2011-02-01 2011-02-01
US201161510520P 2011-07-22 2011-07-22
US201161541287P 2011-09-30 2011-09-30
PCT/US2011/065794 WO2012087908A1 (en) 2010-12-22 2011-12-19 Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota

Publications (1)

Publication Number Publication Date
BR112013015796A2 true BR112013015796A2 (pt) 2017-03-21

Family

ID=45444771

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013015796A BR112013015796A2 (pt) 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
BR112013015786-0A BR112013015786A2 (pt) 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013015786-0A BR112013015786A2 (pt) 2010-12-22 2011-12-19 composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante

Country Status (13)

Country Link
EP (4) EP3957332A1 (pt)
JP (2) JP2014507400A (pt)
KR (5) KR102498607B1 (pt)
CN (1) CN103533963B (pt)
AU (2) AU2011354599B2 (pt)
BR (2) BR112013015796A2 (pt)
CA (3) CA2822693C (pt)
IL (1) IL227003A (pt)
MX (2) MX2013007365A (pt)
NZ (2) NZ612312A (pt)
RU (2) RU2592685C2 (pt)
SG (2) SG191270A1 (pt)
WO (2) WO2012087908A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
WO2012087908A1 (en) * 2010-12-22 2012-06-28 Ge Healthcare Limited Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
WO2014076179A1 (en) * 2012-11-14 2014-05-22 Affibody Ab New polypeptide
JP2016513098A (ja) * 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
CN103948947A (zh) * 2013-05-08 2014-07-30 南京市第一医院 以cd13为分子靶点、ngr为配体的放射性核素分子探针及其标记技术和应用
US10646600B2 (en) 2013-06-27 2020-05-12 Imperial Innovations Limited HER2 polypeptides useful for imaging and monitoring tumors and cancers
CN103833829A (zh) * 2014-01-07 2014-06-04 江苏省原子医学研究所 一种放射性18F标记的靶向肿瘤血管Anxa1显像药物18F-AL-NOTA-IF7及其制备方法
CN103951754B (zh) * 2014-03-26 2016-08-24 中国药科大学 一种靶向治疗和检测双功能的抗肿瘤双特异性小型化抗体
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3303349B1 (en) 2015-05-26 2022-07-06 The Regents of the University of California Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
WO2017156034A1 (en) * 2016-03-10 2017-09-14 Becton, Dickinson And Company Methods of evaluating a cellular sample for her-2/neu expression and compositions for practicing the same
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
CN110251695B (zh) * 2019-07-10 2021-12-21 莎穆(上海)生物科技有限公司 一种靶向her2的放射性配合物及其制备方法和应用
WO2021122729A1 (en) 2019-12-18 2021-06-24 Bracco Imaging Spa Anti-her2 polypeptides derivatives as new diagnostic molecular probes
US20230203129A1 (en) 2019-12-18 2023-06-29 Bracco Imaging S.P.A. Anti-her2 polypeptides derivatives as new diagnostic molecular probes
KR102502287B1 (ko) 2020-04-17 2023-02-22 앱클론(주) 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체
CN114206398A (zh) * 2020-04-30 2022-03-18 霍伯生物技术公司 人类患者中her2表达的可视化

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
JP4871126B2 (ja) * 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2008049866A1 (en) * 2006-10-27 2008-05-02 Affibody Ab New chelating compound
US8303960B2 (en) * 2007-02-27 2012-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2012087908A1 (en) * 2010-12-22 2012-06-28 Ge Healthcare Limited Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
WO2012087912A1 (en) * 2010-12-22 2012-06-28 Ge Healthcare Limited Her2 binding peptides labelled with a 18f - containing organosilicon compound

Also Published As

Publication number Publication date
KR20210059048A (ko) 2021-05-24
MX2013007365A (es) 2013-09-26
EP2654804A1 (en) 2013-10-30
AU2011354599A1 (en) 2013-07-25
RU2592685C2 (ru) 2016-07-27
NZ612312A (en) 2015-02-27
SG191292A1 (en) 2013-07-31
JP2014503546A (ja) 2014-02-13
EP3957332A1 (en) 2022-02-23
KR20130132935A (ko) 2013-12-05
KR20140045312A (ko) 2014-04-16
CN103491984A (zh) 2014-01-01
AU2011349482A1 (en) 2013-07-25
SG191270A1 (en) 2013-07-31
JP2014507400A (ja) 2014-03-27
IL227003A (en) 2017-03-30
RU2013128358A (ru) 2015-01-27
BR112013015786A2 (pt) 2019-02-19
CA3159948A1 (en) 2012-07-19
EP2654803A1 (en) 2013-10-30
EP2654803B1 (en) 2021-08-18
WO2012087908A1 (en) 2012-06-28
NZ612161A (en) 2015-04-24
RU2013128361A (ru) 2015-01-27
KR20230034403A (ko) 2023-03-09
WO2012096760A1 (en) 2012-07-19
CA2822693C (en) 2022-08-16
AU2011354599B2 (en) 2016-09-29
EP3936155A1 (en) 2022-01-12
CA2822693A1 (en) 2012-07-19
MX2013007371A (es) 2014-05-27
CN103533963B (zh) 2015-12-02
CN103533963A (zh) 2014-01-22
KR20180042442A (ko) 2018-04-25
KR102498607B1 (ko) 2023-02-13
CA2822815A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
BR112013015796A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
BR112013015798A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
EP2535339A4 (en) POLYMORPHES OF DASATINIB, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF
BR112013033811A2 (pt) composição, método de preparação da composição, e, composto
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
HK1232229A1 (zh) '- '-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
BR112012023355A2 (pt) composto, composição farmacêutica e método de ruptura da interação nek2/hec1
ITTO20110630A1 (it) Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
HRP20180793T1 (hr) Farmaceutski pripravak i oblik doziranja koji sadrži dronedaron, te postupak njegove priprave
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL230484A (en) "6- (n- (7-Chloro-1-Hydroxy-1, 3-Dihydrobenzo [c] [1,2] Oxaborol-5-Yl) - Methylbenzoforan-3 - Carbamamide and a Pharmaceutical Preparation
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
IT1401757B1 (it) Dispositivo protesico impiantabile e procedimento di solvent casting per la sua fabbricazione.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]